Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

bioMerieux and Illumina sign agreement to launch NGS epidemiology solution

bioMerieux, a provider of in vitro diagnostics, and Illumina, a provider of integrated systems for analysis of genetic variation, have signed an exclusive agreement to launch a next-generation sequencing, or NGS, epidemiology solution to monitor bacterial infections.

Published By MarketLine
25 Nov 2014
NewsWire
NewsWire

Skystar reports higher Q3 net income, reiterates guidance for fiscal 2014

Skystar Bio-Pharmaceutical Company, a provider of veterinary healthcare and medical care products, has reported that net income for the third quarter ended September 30, 2014 was $4.91 million, or $0.57 per diluted share, compared to $3.73 million, or $0.49 per diluted share, for the same quarter ended September 30, 2013. For fiscal 2014, the company has reiterated its revenue guidance range to be between $46 million and $50 million.

Published By MarketLine
25 Nov 2014
NewsWire
NewsWire

ALK-Abello reports higher Q3 net profit, provides annual outlook

ALK-Abello A/S, a Denmark-based pharmaceutical company, has reported that net profit for the third quarter ended September 30, 2014 was DKK26 million, or DKK2.63 per diluted share, compared to DKK9 million, or DKK0.92 per diluted share, for the same quarter ended September 30, 2013. For 2014, the company expects revenue to be approximately DKK2.4 billion and EBITDA to be approximately DKK450 million.

Published By MarketLine
25 Nov 2014
NewsWire
NewsWire

Bio-Rad receives premarket approval from FDA for HIV 1/2 supplemental assay

Bio-Rad Laboratories, Inc., a provider of life science research and clinical diagnostic products, has received premarket application approval from the FDA for its Geenius HIV 1/2 supplemental assay.

Published By MarketLine
25 Nov 2014
NewsWire
NewsWire

Merck's acute coronary syndrome study meets primary and secondary endpoints

Merck & Co., Inc. has announced that the investigational IMPROVE-IT study for VYTORIN, in patients with acute coronary syndrome, met its primary and secondary composite efficacy endpoints.

Published By MarketLine
25 Nov 2014
NewsWire
NewsWire

International Isotopes Q3 net loss down

International Isotopes Inc., a provider of nuclear medicine calibration and reference standards, has reported that net loss attributable to the company for the third quarter ended September 30, 2014 was $267,487, compared to a net loss attributable to the company of $424,107 for the same quarter ended September 30, 2013.

Published By MarketLine
25 Nov 2014
NewsWire
NewsWire

BMS announces encouraging data from Phase IIIb rheumatoid arthritis analyses

Bristol-Myers Squibb Company, or BMS, has announced encouraging data from new sub-analyses of the Phase IIIb Assessing Very Early Rheumatoid arthritis Treatment, or AVERT, trial that investigated the use of Orencia plus methotrexate, or MTX, in biologic and MTX-naive citrullinated protein, or CCP, positive early moderate to severe rheumatoid arthritis, or RA, patients.

Published By MarketLine
25 Nov 2014
NewsWire
NewsWire

Intellipharmaceutics appoints new CFO

Intellipharmaceutics International Inc., a developer of generic controlled-release and targeted-release oral solid dosage drugs, has appointed Domenic Della Penna as its new CFO.

Published By MarketLine
25 Nov 2014
NewsWire
NewsWire

SunLink Health Systems Q1 net loss down

SunLink Health Systems, Inc., a provider of healthcare and pharmacy services, has reported that net loss for the first quarter ended September 30, 2014 was $413,000, or $0.04 loss per share, compared to a net loss of $1.16 million, or $0.12 loss per share, for the same quarter ended September 30, 2013.

Published By MarketLine
25 Nov 2014
NewsWire
NewsWire

Target and Kaiser partner to launch four Target clinics in California

Target Corporation, an American retailing company, and Kaiser Permanente, a provider of managed care services, have partnered to launch four Target clinics in Southern California in November and December.

Published By MarketLine
25 Nov 2014

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.